Empagliflozin Intermediate Sourcing: Buyers Guide

Why Empagliflozin Intermediate Demand Is Accelerating

Empagliflozin — the SGLT2 inhibitor behind Jardiance, Glyxambi, and Synjardy — generated $8 billion in global revenue for Boehringer Ingelheim and Eli Lilly in 2024 (Mordor Intelligence, SGLT2 Market Report 2026). That revenue stream is now fragmenting as patent protections expire region by region, creating a cascade of intermediate demand.

India’s market tells the story most clearly: unit sales doubled from 1.95 million to 3.46 million per month within four months of patent expiry (Business Standard / Pharmarack, July 2025). Every one of those tablets requires empagliflozin API — and every kilogram of API requires intermediates. The global SGLT2 inhibitor market is projected to reach $19.76 billion by 2031 (Mordor Intelligence), with empagliflozin holding the single largest molecule share.

For intermediate buyers, the implication is straightforward: demand is not theoretical. It is already translating into procurement volume.

The Empagliflozin Synthesis Route: Where the Critical Intermediates Sit

Empagliflozin (CAS 864070-44-0) contains six chiral centers — three on the glucose ring (C2–C6) and one on the tetrahydrofuran ring (C3). The β-C-glycosidic linkage at the anomeric carbon is the single most critical stereochemical feature: the α-anomer is pharmacologically inactive and must be controlled below 0.1% in the final API (CATO Chemical, Empagliflozin Impurity Guide).

The industrial synthesis route disclosed by Boehringer Ingelheim (Wang et al., Organic Letters, 2014, 16, 4090–4093; DOI: 10.1021/ol501755h) proceeds through four key stages, each generating a commercially significant intermediate:

Three observations matter for procurement:

First, the (S)-tetrahydrofuran moiety is installed in Stage 1 and carried unchanged through every subsequent step. If the intermediate retest date has expired and the ee% has drifted, that error propagates into the final API with no correction opportunity.

Second, the β-anomeric selectivity is created in Stage 3 during the glycosidation sequence. The Wang et al. process achieves β-selectivity through a thermodynamic equilibration (α:β methyl furanoketal → β-pyranoketal over 3–5 hours at 40°C) followed by a stereoselective silane reduction (ScienceDirect, Comprehensive Chirality 2024). This is the step where α-anomer impurity is either controlled or lost.

Third, Acetoxy Empagliflozin (CAS 915095-99-7) is the last protected intermediate before deprotection. Its purity, anomeric ratio, and impurity profile directly predict the quality of the final API — making it the single most informative intermediate to evaluate when selecting a supplier.

Six Chiral Centers, Six Quality Control Checkpoints

Empagliflozin’s molecular structure contains six stereocenters in fixed configuration: (2S,3R,4R,5S,6R) on the glucopyranose ring and (3S) on the tetrahydrofuran ring. Each one is a separate quality control event — not a single “chiral purity” number on a COA.

Five of the six centers (C3–C6 on glucose) originate from the D-glucose starting material — they are structurally inherent and rarely invert under normal process conditions. The two that can invert and must be explicitly controlled are:

• C2 (anomeric carbon):The β→α inversion happens during glycosidation. Controlling it requires the right combination of thermodynamic equilibration time (3–5 hours), silane reduction conditions (Et₃SiH/AlCl₃ or BF₃·OEt₂), and crystallization purification. A COA that only lists “purity 99%” without specifying the α-anomer fraction is incomplete.
• THF C3:The (S)-configuration comes from (S)-3-hydroxytetrahydrofuran (CAS 86087-23-2). If the SNAr etherification in Stage 1 uses racemic or low-ee% THF, the wrong stereochemistry is locked in permanently — no downstream step can correct it.

Four Key Intermediates: What to Check on Each COA

Not every intermediate in the synthesis route is commercially traded at volume. Four intermediates dominate procurement discussions, and each has specific COA fields that matter more than a generic “assay ≥98%” claim.

Among these four, Acetoxy Empagliflozin (CAS 915095-99-7) is the most procurement-significant. It sits at the final protected stage — its anomeric purity, impurity profile, and residual solvent levels directly predict the quality of the deprotected API. A supplier who cannot provide the α-anomer fraction on this intermediate’s COA is, in practical terms, telling you they do not control the stereochemistry that defines empagliflozin’s pharmacological activity.

Three Scale-Up Challenges That Directly Affect Intermediate Quality

The Wang et al. process was implemented at metric-ton scale for Jardiance’s commercial launch (Org. Lett. 2014, 16, 4090). Scaling from lab to production, however, creates three quality risks that intermediate buyers should understand:

Cryogenic Organometallic Steps

The I/Mg exchange (i-PrMgCl·LiCl at −20°C) or Br/Mg exchange (n-BuLi at −78°C) requires strict cryogenic control. Temperature excursions above −40°C during the bromide route lead to reduced β-selectivity and elevated α-anomer formation. At commercial scale, efficient mixing at −78°C is a recognized engineering challenge — inadequate mixing creates local hot spots where stereochemistry drifts (DearChem, Scale-up Analysis, CN105399735A).

Moisture Sensitivity

The organolithium and organomagnesium intermediates are pyrophoric and moisture-sensitive. Water content above 0.1% in the THF solvent or in the aryl halide intermediate (CAS 915095-89-5) deactivates the metalation, reduces yield, and generates degradation products 9a/b documented in the Wang et al. paper. This is why the COA’s Karl Fischer moisture data matters for this intermediate specifically — not as a generic QC field, but as a predictor of whether the downstream glycosidation will work.

Silane Reduction Stereochemical Window

The Et₃SiH/AlCl₃ reduction in CH₂Cl₂/MeCN at −5°C to +25°C creates the β-anomeric carbon via an oxocarbenium ion intermediate. The facial selectivity depends on Lewis acid concentration, silane addition rate, and temperature. Process deviations shift the α:β ratio — and once the ratio is set, only crystallization of the per-acetylated intermediate (from ethanol) can remove the α-anomer.

If crystallization is skipped or incomplete, the α-impurity carries into the final API (ScienceDirect, Comprehensive Chirality 2024). This explains why the improved route by Shi et al. (Chinese Journal of Pharmaceuticals, 2018, 49, 1100) reports α-empagliflozin content <0.1% only after optimized crystallization.

Four Questions to Ask Before Ordering Empagliflozin Intermediates

1. “Can you provide the α-anomer fraction for Acetoxy Empagliflozin on the COA?”
   If the answer is “we only report total purity,” the supplier does not control the stereochemistry that defines empagliflozin’s activity. The α-anomer is a designated impurity (CAS 1620758-33-9)with its own reference standard — it is quantifiable and should appear on every COA for this intermediate.
2. “What is the ee% of the (S)-THF moiety in the diaryl ether intermediates (CAS 915095-89-5 / 915095-94-2)?”
   The (S)-tetrahydrofuran stereochemistry is set in Stage 1 and cannot be corrected downstream. ee% below 99.5% means the (R)-epimer is present in the side chain — a structural impurity that no amount of final crystallization can remove.
3. “What residual solvent levels do you report, and against which ICH limits?”
   The empagliflozin synthesis uses DCM, toluene, ethyl acetate, THF, and acetonitrile — all Class 2 solvents per ICH Q3C. A COA that lists “residual solvents: complies” without naming the specific solvents and their ppm values is not useful for ICH Q3C compliance assessment.
4. “What scale have you manufactured this intermediate at, and what was the batch-to-batch anomeric ratio consistency?”
   Lab-scale COA data does not predict commercial-scale behavior for empagliflozin intermediates — the cryogenic and moisture-sensitive steps behave differently at 100-liter versus 5-liter scale. Ask for at least three consecutive commercial-batch COAs and compare the α-anomer numbers. Consistency across batches is more informative than a single impressive number.

Frequently Asked Questions

What is the most important intermediate for empagliflozin?

Acetoxy Empagliflozin (CAS 915095-99-7) — the per-acetylated intermediate that sits at the last protected stage before deacetylation. Its anomeric purity (α:β ratio) directly predicts the API’s pharmacological quality.

Why does the α-anomer matter in empagliflozin?

The α-anomer at the anomeric carbon (C2) is pharmacologically inactive. It is a designated impurity with its own CAS number (1620758-33-9) and must be controlled below 0.1% per standard API specifications. It forms during the glycosidation and silane reduction steps and can only be removed by crystallization of the per-acetylated intermediate.

When will empagliflozin generics enter the US market?

The foundational composition patent (US7579449) with pediatric extension expires approximately February 2029. Method-of-use patents extend to December 2034. Actual generic entry timing depends on Hatch-Waxman Paragraph IV litigation outcomes (TheraRadar; DrugPatentWatch).

How many chiral centers does empagliflozin have?

Six: five on the glucopyranose ring (C2–C6, configuration 2S,3R,4R,5S,6R) and one on the tetrahydrofuran ring (C3, configuration S). The β-anomeric configuration at C2 and the (S)-THF configuration are the two that require active process control — the others are inherent to the D-glucose starting material.

What ee% should (S)-3-hydroxytetrahydrofuran have for empagliflozin synthesis?

≥99.5% ee. The (S)-THF stereochemistry is installed in Stage 1 and propagates unchanged through the entire synthesis. ee% below this threshold introduces the (R)-THF epimer as a structural impurity that cannot be removed by downstream purification.

References

1. Wang, X.-J.; Zhang, L.; Byrne, D.; Nummy, L.; Weber, D.; Krishnamurthy, D.; Yee, N.; Senanayake, C. H. “Efficient Synthesis of Empagliflozin, an Inhibitor of SGLT-2, Utilizing an AlCl₃-Promoted Silane Reduction of a β-Glycopyranoside.” Organic Letters, 2014, 16(16), 4090–4093. DOI: 10.1021/ol501755h
2. Shi, K.; Chen, L.; Li, J.; Ren, F.; Yang, C.; Gou, X. “Improved Synthetic Process of Empagliflozin.” Chinese Journal of Pharmaceuticals, 2018, 49(8), 1100. IAcademic
3. “Industrial Applications of Asymmetric Synthesis: Empagliflozin.” Comprehensive Chirality(2nd Ed.), 2024, Section 9.22.4. ScienceDirect
4. “Jardiance Patent Landscape — 26 OB Patents, 11 Families.” Updated 2026-05-15. TheraRadar
5. “Jardiance / Empagliflozin NDA 204629.” DrugPatentWatch
6. Economic Times. “As Empagliflozin Goes Off Patent, 71 Copies Roll Out in a Month.” April 9, 2025. Economic Times
7. Mordor Intelligence. “SGLT2 Market Size & Share Report, Growth Drivers 2031.” Mordor Intelligence
8. CATO Chemical. “Empagliflozin Impurity Standard Guide — Regulatory Requirements for ANDA.” CATO Chemical